scorecard
  1. Home
  2. finance
  3. A small boutique landed a lucrative lead role on the $8.7 billion Novartis-AveXis deal

A small boutique landed a lucrative lead role on the $8.7 billion Novartis-AveXis deal

A small boutique landed a lucrative lead role on the $8.7 billion Novartis-AveXis deal

Suarez Celebration

Julian Finney/Getty

  • Dyal Co., a small M&A boutique, landed a lead role on the the $8.7 billion Novartis-AveXis deal.
  • The firm has roughly 15 employees and is led by ex-Goldman Sachs rainmaker Gordon Dyal.
  • Dyal was the former co-chairman of investment banking at Goldman, where he spent years leading M&A deals in Europe.
  • He's leveraged that experience to land advisory roles with multinational companies since starting his own firm.

Novartis on Monday announced$4, which $4 for the Swiss drugmaker.

The deal is expected to close in the middle of this year, and if it does, it will result in a hefty payday for Dyal Co., a small mergers-and-acquisitions advisory firm that landed the lucrative job of serving as Novartis' banker on the deal. Goldman Sachs and Centerview Partners advised AveXis.

Deal fees for large biotech transactions run into the tens of millions, which isn't chump change for any M&A-advisory firm, let alone a boutique like Dyal, which has roughly 15 employees.

The mandate is yet another coup for Gordon Dyal, the ex-Goldman Sachs rainmaker for whom the small M&A shop is named.

So who is Dyal?

Gordon Dyal was a partner at Goldman Sachs for 16 years, $4 in 2011 before retiring from the firm to set off on his own in 2015. He spent much of his time at Goldman doing M&A in Europe, serving as co-head of European M&A and investment banking before taking the role of global head M&A in 2004.

He's also reportedly a big-game hunting enthusiast and $4.

Since leaving Goldman he's leveraged his European contacts and experience to hunt down advisory roles for multinational corporate clients.

In addition to advising Swiss behemoth $4, a nearly $215 billion company, Dyal Co. landed a lead role on the $43 billion sale of Swiss agriculture and chemicals giant Syngenta to ChemChina $4. It also advised $4, a $60 billion Swiss power and automation firm, on its $4 business in September.

Dyal Co. advised $4, a $40 global billion plastics and chemicals firm, on a $4.

Since landing the Syngenta role, Dyal has $4. He has brought in Tim Quandt and Paresh Lala from Goldman Sachs, as well Grant Curry and Howard Sun, formerly of UBS and JPMorgan, respectively.

Jill Dyal, Gordon's wife who also worked at Goldman Sachs for a decade and left as a VP in M&A in 2009, is the COO, CFO, and managing partner at Dyal Co, $4.

NOW WATCH: $4

READ MORE ARTICLES ON



Popular Right Now



Advertisement